Freeman Spogli Institute for International Studies Program on Energy and Sustainable Development Stanford University


New, but Not Improved? Incorporating Comparative-Effectiveness Information into FDA Labeling

Journal Article

Randall S. Stafford - Stanford University
Todd H. Wagner - Stanford University
Lavori PW

Published by
New England Journal of Medicine, Vol. epub
August 12, 2009

New technologies, including prescription drugs and medical devices, are a major driver of increases in U.S. health care expenditures, which have grown by an estimated 71% since 2000.1 The U.S. market for drugs and devices is regulated by the Food and Drug Administration (FDA), which scrutinizes clinical trial data for evidence of safety and efficacy. Although the FDA has been criticized for missteps and inefficiencies in its approval process, these are not the causes of increasing health care expenditures. More relevant is FDA oversight of the labeling and promotion of medical products.